



***Nanomed2020 intends to bring more nanomedicine products to European patients***

***Nanomed2020 is a project supported by the European Commission***

***Paris, France, October 03, 2012 — Nanobiotix announced today a collaboration with key European nanomedicine players which is funded by the European Commission. This strong partnership of relevant stakeholders aims to identify key areas of nanomedicine with novel concepts for translation of nanomedical innovations into clinical practice. The project called “Nanomed2020” started on 1<sup>st</sup> September 2012 and has duration of 18 months.***

Making Europe a center for nanomedicine research, development and translation is the goal of this project. To achieve this goal the proposed project unites partners already representing the largest network of active stakeholders in the nanomedicine area as of today in Europe, embracing roughly 200 Universities, Research Institutes, Hospitals and Public Health Institutions, Small and Medium-sized Enterprises (SMEs) and small and large industry organizations.

What are the needs and the problems? Excellent academic research groups may need to better understand the market and the medical needs. There are a large number of pharmaceutical and medtech companies that have a comprehensive and direct access to market but these companies struggle to handle radical innovation. At the same time, there is a small numbers of SMEs trying to add new innovation onto the market, but these few companies are too small to exploit the large potential of nanomedicine. A consolidated pan-European approach to structure this field is therefore highly needed to bring nanomedicine products more efficiently to patients.

“We are proud that we were able to receive funding for this project from the European Commission” said Dr. Sebastian Lange, the coordinator of this project at VDI/VDE-IT, “seven renowned nanomedicine players from six European countries hope to build a pertinent European nanomedicine community involving all key players. We aim to define the resources, gaps and needs for development and implementation of nanomedicine research into marketable innovations to be used by doctors for the benefit of patients.”

The Nanomed2020 project is an opportunity for all stakeholders from industry, academia, clinic and public authorities to provide the European Commission with input for a future nanomedicine topic within Horizon 2020. This will make nanomedicine an important contributor to the future European healthcare system with a beneficial impact on improved treatment for patients and on social challenges such as ageing population.

“Being a leader in the nanomedicine field with therapeutic products in clinical development we are interested to grow and mature the European environment and infrastructure for nanomedicine” commented Laurent Levy, CEO of Nanobiotix. “We will therefore contribute with our 15 years of experience in this field, our network and commercial knowledge to this project to show that nanomedicine can overcome societal challenges and has a huge economic potential through an improved and cost-effective health care.”

**ABOUT Nanomed 2020**

The Nanomed2020 Support Action project, funded with a contribution of 500 000€ by the European Commission under the Work Programme FP7-HEALTH-2012 (Area 2012.4.1-5: Preparing the future

for health research and innovation) was launched on 1st September 2012 and is planned to have a duration of 18 months.

Partners of the Nanomed2020 project:

- VDI/VDE-IT (Coordinator), [www.vdivde-it.de](http://www.vdivde-it.de)
- CLINAM Foundation, [www.clinam.org](http://www.clinam.org)
- Instituto de Salud Carlos III, [www.isciii.es](http://www.isciii.es)
- Bioanalytik Muenster e.V., [www.bioanalytik-muenster.de](http://www.bioanalytik-muenster.de)
- Nanobiotix, [www.nanobiotix.com](http://www.nanobiotix.com)
- Fondazione Don Carlo Gnocchi ONLUS, [www.dongnocchi.it](http://www.dongnocchi.it)
- SINTEF, [www.sintef.no](http://www.sintef.no)

For more information about the project consult: <http://www.etp-nanomedicine.eu/public/news-events/news/start-of-nanomed-2020>

The website [www.nanomed2020.eu](http://www.nanomed2020.eu) will be launched soon and latest news on Nanomedicine research, strategic challenges and innovation concepts will be available there.

### **ABOUT Nanomedicine**

Nanomedicine is understood to be the enabling instrument for personalized, targeted and regenerative medicine by delivering the next level of new drugs, treatments and implantable devices to clinicians and patients. Beyond that, Nanomedicine provides important new tools to deal with the grand challenge of an ageing population and is thought to be instrumental for improved and cost effective health-care, one crucial factor for making medicines and treatments available and affordable to all.

### **ABOUT NANOBIOTIX– [www.nanobiotix.com](http://www.nanobiotix.com)**

Nanobiotix, pioneer and leader in nanomedicine, has developed a revolutionary concept dedicated to the local treatment of cancer. Nanobiotix is focused on the development of NanoXray, a pipeline of patented products, which are based on the physical mechanism of action of the nanoparticles interacting with X-rays and maximizing radiation effect into tumor cells. NanoXray products enhance the efficacy of the radiotherapy in the tumor without increasing healthy tissues damages. NanoXray products can be used with existing standard radiation equipments available in almost every hospital world-wide.

Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo that was incorporated in 2003 and has been primarily funded by leading European venture capital firms. The company has more than 30 employees and is based in Paris, France. Nanobiotix's objective is to enhance its leading position in the nanomedicine field on the main oncology markets. Its pipeline of universal products enable to target the major indications of cancers (breast cancer, prostate cancer, lung cancer...), leading to a potential market of several billion dollars. Thanks to the physical based mechanism of action of its nanoparticles, Nanobiotix brings out a unique business model with much lower risk than classic drug development, enabling a faster and less expensive time to market.

### **Nanobiotix**

Laurent Levy

[laurent.levy@nanobiotix.com](mailto:laurent.levy@nanobiotix.com)

### **Nanomed2020 Coordinator**

Dr. Sebastian Lange

[secretariat@etp-nanomedicine.eu](mailto:secretariat@etp-nanomedicine.eu)

+49 30 310078 299